Retatrutide vs Mazdutide: What the Research Compares

Retatrutide is an investigational medicine studied in clinical trials and is not approved for marketing in the United States or the European Union. Mazdutide is a prescription medicine approved in China for chronic weight management and remains investigational in other regions, including the United States. Decisions about either medicine belong with a prescribing clinician. This page is for educational purposes only and is not medical advice; consult a licensed physician about any medicine and about whether any published finding has relevance to an individual situation.

Is There a Head to Head Trial of Retatrutide and Mazdutide?

No. As of the literature summarised here, no randomized controlled trial has randomised participants to retatrutide in one arm and mazdutide in another. The two molecules appear together only inside systematic reviews and network meta-analyses that pool separate placebo controlled and active comparator trials and then estimate indirect comparisons. A 2024 updated systematic review and network meta-analysis of seven GLP-1 receptor agonists and polyagonists for weight loss in patients with obesity or overweight assembled exactly that kind of indirect evidence base rather than direct comparison data (PMID 39305981), and a 2026 BMJ network meta-analysis of drugs for adults with overweight or obesity took a similarly indirect approach across a wider drug list (PMID 42419792).

Because the comparison is indirect, researchers in these reviews relied on shared comparators such as placebo, and on the assumption that trial populations, background care and outcome definitions were similar enough to be linked statistically. That assumption is a recognised limitation rather than a technicality, and it is one reason the sections below present the two evidence bases side by side instead of declaring any difference between them.

Where the Two Appear Together: The Pooled Evidence Base

Several reviews published between 2024 and 2026 placed incretin based single, dual and triple receptor agonists into one comparative framework. Each covered a different slice of the field.

Across these reviews, researchers reported that multi receptor agonists produced larger average weight reduction than single receptor GLP-1 agonists in pooled randomized trial data (PMID 41711462), and a 2026 BMJ Medicine network meta-analysis reported that efficacy and safety estimates differed across the GLP-1 based drug class in adults with overweight or obesity without diabetes (PMID 42688617). None of these analyses rested on a direct retatrutide versus mazdutide randomisation, so differences between the two molecules in such models carry the uncertainty of indirect estimation.

Class and Mechanism

Retatrutide

Retatrutide has been described in the obesity pharmacotherapy literature as a triple receptor agonist acting at the GIP, GLP-1 and glucagon receptors, and a 2025 systematic review of emerging pharmacotherapies for obesity catalogued it among investigational agents in that multi receptor group (PMID 39952695). A 2026 perspective review on multi receptor agonists and next generation metabolic modulators placed triple agonism within the broader shift from single hormone mimicry toward combined receptor engagement (PMID 41948476).

Mazdutide

Mazdutide has been described as a dual GLP-1 and glucagon receptor agonist, and a 2026 class specific systematic review and meta-analysis examined efficacy and safety for dual GLP-1 and glucagon receptor agonism in overweight and obesity as a group (PMID 42811393). A 2025 review focused on glucagon receptor agonist combinations discussed the rationale for adding glucagon receptor activity, including its proposed effects on energy expenditure and hepatic fat, alongside the monitoring questions that accompany it (PMID 40734920).

The shared element is glucagon receptor agonism; the point of divergence in published descriptions is GIP receptor activity, which features in the triple agonist profile and not in the dual GLP-1 and glucagon profile (PMID 39952695). Analytical chemistry work has also begun to characterise this expanding class: a 2026 study developed and validated a multiplexed LC-HRMS method covering nine GLP-1 receptor agonists for pharmaceutical application (PMID 42603384).

Regulatory Status

• Retatrutide: an investigational medicine evaluated in clinical trials. Published reviews of emerging obesity pharmacotherapy listed it among agents still in development rather than among marketed products (PMID 39952695).
• Mazdutide: approved in China for chronic weight management and prescribed there under that authorisation, while remaining an investigational medicine in the United States and the European Union.
• Both: availability, labelling and permitted indications are set by national regulators and change over time. A prescribing clinician is the appropriate source for current status in any given country.

Endpoints Beyond Body Weight

Comparative reviews have extended past weight change. A 2025 network meta-analysis of incretin drugs assessed glycaemic control, body weight and blood pressure together in adults with overweight or obesity with and without type 2 diabetes, and reported that incretin based agents affected more than one of these outcomes (PMID 39968298). A 2026 review in The Lancet Diabetes and Endocrinology summarised multisystem effects of obesity medications beyond weight loss, spanning cardiovascular, hepatic and renal outcomes (PMID 42208956). The depth of outcome data is uneven across molecules, and the reviews reported that long term outcome trials were further advanced for some agents than others (PMID 42419792).

Paediatric evidence is a further gap. A 2026 review of pharmacotherapy for paediatric obesity examined what adult weight loss medication data can and cannot support in younger populations and described the evidence as limited for newer multi receptor agents (PMID 42871568).

Adverse Events: What Studies Report

Published safety summaries for both mechanisms centre on gastrointestinal tolerability. A 2026 class specific systematic review and meta-analysis of dual GLP-1 and glucagon receptor agonism reported that gastrointestinal events, including nausea, vomiting and diarrhoea, were the most frequently recorded adverse events in the pooled trials (PMID 42811393). A 2026 meta-analysis of incretin based dual and triple agonists in overweight or obese individuals likewise reported gastrointestinal adverse events as the dominant tolerability signal across the pooled studies (PMID 41711462).

Discontinuation and dose escalation patterns have also been examined: a 2026 BMJ Medicine network meta-analysis assessed safety alongside efficacy for GLP-1 based drugs in adults with overweight or obesity without diabetes and reported differences in adverse event frequency across the class (PMID 42688617). For glucagon receptor containing combinations specifically, a 2025 review discussed heart rate and hepatic parameter monitoring as areas raised by the mechanism (PMID 40734920). A 2026 perspective review noted that controversies about long term safety and durability of effect remain open for multi receptor agonists generally (PMID 41948476).

What the Indirect Comparison Can and Cannot Settle

1. Trial populations differed. Programmes for the two molecules enrolled different regions, baseline body mass index ranges and diabetes status mixes, which network meta-analyses must adjust for rather than eliminate (PMID 39968298).
2. Follow up lengths differed. Reviews reported that trial durations across the class varied, limiting comparison of maintained effect (PMID 42419792).
3. Escalation schedules differed. Tolerability depends heavily on titration design, and pooled safety estimates reflect the schedules used in the source trials (PMID 42811393).
4. Outcome breadth differed. Cardiovascular, hepatic and renal endpoints were reported to varying degrees across agents (PMID 42208956).

For these reasons, the published record supports description of each molecule's evidence base and of the indirect models that include both, and it does not support a direct ranking of one against the other.

Related Reading

• Retatrutide: what the research describes
• Mazdutide: what the research describes

References

• Seven glucagon-like peptide-1 receptor agonists and polyagonists for weight loss in patients with obesity or overweight: an updated systematic review and network meta-analysis of randomized controlled trials (Metabolism: clinical and experimental, 2024)
• Emerging pharmacotherapies for obesity: A systematic review (Pharmacological Reviews, 2025)
• Beyond weight loss: multisystem benefits of obesity medications (The Lancet Diabetes & Endocrinology, 2026)
• Comparative effects of drugs for adults with overweight or obesity: systematic review and network meta-analysis (BMJ, 2026)
• Comparative efficacy of incretin drugs on glycemic control, body weight, and blood pressure in adults with overweight or obesity and with/without type 2 diabetes: a systematic review and network meta-analysis (Frontiers in Endocrinology, 2025)
• Incretin-Based Dual and Triple Agonists in Overweight or Obese Individuals: A Systematic Review and Meta-Analysis (Cardiology in Review, 2026)
• Comparative efficacy and safety of glucagon-like peptide 1 based drugs for weight loss in adults with overweight or obesity without diabetes: network meta-analysis of randomised controlled trials (BMJ Medicine, 2026)
• Obesity pharmacotherapy reimagined: The era of multi-receptor agonists and next-generation metabolic modulators, perspectives and controversies (Metabolism Open, 2026)
• The pharmacotherapy for pediatric obesity: insights and challenges from adult weight-loss medications (Journal of Diabetes and Metabolic Disorders, 2026)
• Emerging concepts in obesity management: focus on glucagon receptor agonist combinations (Drugs in Context, 2025)
• Development and validation of a multiplexed LC-HRMS method for nine GLP-1 receptor agonists and its pharmaceutical application (Journal of Chromatography A, 2026)
• Efficacy and Safety of Dual GLP-1/Glucagon Receptor Agonism in Overweight and Obesity: A Class-Specific Systematic Review and Meta-Analysis (Diabetes, Obesity & Metabolism, 2026)